The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial

References

• Celebrex Summary of Product Characteristics. The electronic Medicines Compendium (eMC). Surrey, UK: Datapharm Communications Ltd, 2011. http://www.medicines.org.uk/EMC/medicine/14534/SPC/Celebrex+100mg+%26+200mg+Capsules/. Accessed July 12, 2011
   Google Scholar
• National Collaborating Centre for Chronic Conditions. Osteoarthritis: national clinical guidelines for care and management in adults. London, UK: Royal College of Physicians, 2008. http://www.nice.org.uk/nicemedia/live/11926/39720/39720.pdf. Accessed January 27, 2011
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE). 2011. http://www.nice.com. Accessed January 27, 2011
   Google Scholar
• Latimer N, Lord J, Grant RL, et al. National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ 2009;339:b2538
   Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247–55
   PubMed Web of Science ®Google Scholar
• Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Longterm (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771–81
   PubMed Web of Science ®Google Scholar
• Kirshner H, Ruland S, Verheugt FW, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675–84
   Google Scholar
• Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665–74
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions. Appendix D, Osteoarthritis: national clinical guidelines for care and management in adults. London: Royal College of Physicians, 2008. http://www.rcplondon.ac.uk/. Accessed January 27, 2011
   Google Scholar
• Chan FKL, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010;376:173–79
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247–55
   PubMed Web of Science ®Google Scholar
• Average Daily Quantities. Leeds, UK: The Information Centre for Health and Social Care, 2011. Available at: http://www.ic.nhs.uk/services/prescribing-support-unit-psu/using-the-service/reference/measures/volume-measures/average-daily-quantities-adq. Accessed July 12, 2011
   Google Scholar
• Latimer N, Lord J, O’Mahony, et al. Value of information in the osteoarthritis setting: cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors. Pharmacoeconomics 2011;29:225–37
   Google Scholar
• NHS Reference Costs 2009–2010. London, UK: Department of Health, 2011. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_123459. Accessed April 1, 2011
   Google Scholar
• British National Formulary (BNF), 2010. http://www.bnf.org. Accessed April 1, 2011
   Google Scholar
• Curtis L. Unit costs of health and social care. Kent, UK: Personal Social Services Research Unit (PSSRU), 2010. http://www.pssru.ac.uk/uc/uc2010contents.htm. Accessed April 1, 2011
   Google Scholar
• Hypertension: management of hypertension in adults in primary care: partial update. London, UK: National Institute for Health and Clinical Excellence (NICE), 2006. Available at: www.nice.org.uk/nicemedia/pdf/CG034NICEguideline.pdf. Accessed April 1, 2011
   Google Scholar
• Guide to the methods of technology appraisal. London, UK: National Institute for Health and Clinical Excellence (NICE), 2008. Available at: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed July 12, 2011
   Google Scholar
• Chan FKL, Wong VWS, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007;369:1621–26
   PubMed Web of Science ®Google Scholar
• Ray WA. Cardiovascular safety of NSAIDs. BMJ 2011;342:c6618
   PubMed Web of Science ®Google Scholar